WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > BioAtla LLC
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Industrial Impact
AbCellera and Versant Ventures | July 28, 2022
AbCellera and Versant Ventures announced a multi-year collaboration to discover therapeutic antibodies for multiple targets selected by Versant’s portfolio of biologics-focused biotechs. Versant and AbCellera already have enabled three of the firm’s stealth-stage companies under previous partnerships. Under the terms of the deal, Versant portfolio companies will have rights to develop and commercialize the resulting therapeutic antibodies. AbCellera will receive resear...
PRNewswire | June 22, 2023
Telix Pharmaceuticals Limited announces it has entered into an agreement to acquire Lightpoint Medical and its SENSEI® radio-guided surgery business. Lightpoint Medical is a United Kingdom-based medical device company specialising in the intra-operative detection of targeted radiopharmaceuticals. SENSEI is an ultra-miniature robotic gamma probe for intracavital use that is able to provide radiopharmaceutical-based surgical guidance ("radio-guided surgery") by enabl...
Express Journal | April 13, 2020
As per the report, the DNA Sequencing Products market is predicted to gain significant returns while registering a lucrative annual growth rate during the foreseen time period. Exposing an enthralling outline of this DNA Sequencing Products industry, the report provides details about the complete valuation of the market, growth opportunities in the business verticals along with a detailed classification of the DNA Sequencing Products market. DNA Sequencing Products Market report is an extensive ...
GlobeNewswire | September 01, 2020
-Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc announced that the first patient was dosed last week in a Phase 2/3 study with VIR-7831 (also known as GSK4182136), a fully human anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus-2) monoclonal antibody, for the early treatment of COVID-19 in patients who are at high risk of hospitalization. The aim of the COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care Early) study, which will enroll approximatel...
Industry Outlook
Whitepaper
Cell and Gene Therapy
Video
Cell and Gene Therapy, Industrial Impact
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE